disitamab vedotin  (MedChemExpress)

Journal: Current Issues in Molecular Biology

Article Title: TNF Signaling Pathway Is the Key Pathway Regulated by Disitamab Vedotin in Bladder Cancer Cells

doi: 10.3390/cimb47050369

Figure Lengend Snippet: DEGs between RC48-treated SW780 cells and control cells. ( A ) Volcano plot of gene expression differences between RC48-treated SW780 cells and control group cells, with red representing upregulated genes, blue representing downregulated genes, and gray representing genes with no significant difference in expression. ( B ) Heatmap of DEGs between the two groups of cells, with red indicating upregulation and blue indicating downregulation. A-1, A-2, A-3, B-1, B-2, and B-3 are numbering of the six groups of cells for transcriptome analysis, with A representing the control group and B representing the Disitamab Vedotin-treated group. Not sig, not significant.

Article Snippet: Disitamab Vedotin (CAS No. 2136633-23-1) was purchased from Selleck (Houston, TX, USA).

Techniques: Control, Gene Expression, Expressing

Journal: Current Issues in Molecular Biology

Article Title: TNF Signaling Pathway Is the Key Pathway Regulated by Disitamab Vedotin in Bladder Cancer Cells

doi: 10.3390/cimb47050369

Figure Lengend Snippet: Enrichment of DEGs between Disitamab Vedotin-treated SW780 cells and control cells. ( A ) The GO enrichment results of DEGs in RC48-treated SW780 cells compared with control cells; all the enriched signaling pathways were upregulated in cells treated with Disitamab Vedotin compared with the control cells. ( B ) The KEGG pathway enrichment results of DEGs in the two groups of cells; all the enriched signaling pathways were upregulated in cells treated with Disitamab Vedotin compared with the control cells. ( C ) The genes corresponding to each enriched pathway, with the size of the circle representing the number of enriched genes. ( D ) The expression difference heatmap of the 33 DEGs enriched in KEGG pathways among all 159 DEGs, in both control and Disitamab Vedotin-treated groups. A-1, A-2, A-3, B-1, B-2, and B-3 are numbering of the six groups of cells for transcriptome analysis, with A representing the control group and B representing the Disitamab Vedotin-treated group.

Article Snippet: Disitamab Vedotin (CAS No. 2136633-23-1) was purchased from Selleck (Houston, TX, USA).

Techniques: Control, Protein-Protein interactions, Expressing

Journal: Current Issues in Molecular Biology

Article Title: TNF Signaling Pathway Is the Key Pathway Regulated by Disitamab Vedotin in Bladder Cancer Cells

doi: 10.3390/cimb47050369

Figure Lengend Snippet: The regulation of Disitamab Vedotin on hub gene expression (mRNA level) in bladder cancer cells was analyzed by qPCR. ( A ) Violin plot of relative mRNA level of the hub genes of control and Disitamab Vedotin-treated SW780 cells. ( B ) Violin plot of relative mRNA level of the hub genes of control and Disitamab Vedotin-treated 5637 cells. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; ns, no significance.

Article Snippet: Disitamab Vedotin (CAS No. 2136633-23-1) was purchased from Selleck (Houston, TX, USA).

Techniques: Gene Expression, Control

Journal: ADMET & DMPK

Article Title: Preclinical pharmacokinetics, distribution, metabolism and excretion of disitamab vedotin

doi: 10.5599/admet.2582

Figure Lengend Snippet: Major metabolic pathways of [ 3 H]-labelled disitamab vedotin in rats/mice. P: plasma, represented by rate, % in B: bile, U: urine, F: faeces, representing and stool, respectively, represented by dose, %; T: tumour tissue, represented by rate, % of F: female and M: male rats with tumour tissue

Article Snippet: Disitamab vedotin (DV) was generated by RemeGen Co., Ltd., as described previously [ ].

Techniques: Clinical Proteomics

Journal: ADMET & DMPK

Article Title: Preclinical pharmacokinetics, distribution, metabolism and excretion of disitamab vedotin

doi: 10.5599/admet.2582

Figure Lengend Snippet: Major metabolic pathways of [ 3 H]-labelled disitamab vedotin in rats/mice. P: plasma, represented by rate, % in B: bile, U: urine, F: faeces, representing and stool, respectively, represented by dose, %; T: tumour tissue, represented by rate, % of F: female and M: male rats with tumour tissue

Article Snippet: Disitamab vedotin (DV), developed by RemeGen.

Techniques: Clinical Proteomics

Journal: Acta Pharmaceutica Sinica. B

Article Title: Resistance to antibody–drug conjugates: A review

doi: 10.1016/j.apsb.2024.12.036

Figure Lengend Snippet: Summary of clinically approved ADCs.

Article Snippet: Disitamab vedotin , Aidixi® , RemeGen , HER2 , mc-VC-PABC , MMAE , 4 , 2021 , GC, UC , Hematologic toxicity , – .

Techniques: